Loading...
XSTO
EGTX
Market cap238mUSD
Jul 10, Last price  
6.08SEK
1D
-0.33%
1Q
1.16%
Jan 2017
-65.26%
IPO
-51.34%
Name

Egetis Therapeutics AB (publ)

Chart & Performance

D1W1MN
XSTO:EGTX chart
P/E
—
P/S
36.82
EPS
—
Div Yield, %
—
Shrs. gr., 5y
38.04%
Rev. gr., 5y
8.94%
Revenues
62m
+35.36%
002,66600000013,585,00028,211,00082,562,00040,662,00038,243,00022,500,00057,600,00046,100,00062,400,000
Net income
-343m
L-0.32%
-559,065-1,345,648-3,800,624-33,246,055-33,857,000-25,549,000-48,420,000-43,836,000-38,223,000-87,935,000-85,003,000-61,429,000-179,121,000-104,730,000-189,500,000-326,900,000-343,600,000-342,500,000
CFO
-267m
L+17.20%
-2,717,199-14,395,782-31,957,000-28,066,000-41,384,000-51,153,000-36,115,000-86,551,000-80,310,000-62,641,000-134,639,000-130,110,000-173,500,000-278,400,000-227,900,000-267,100,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Egetis Therapeutics AB (publ) is a pharmaceutical enterprise committed to progressing drug development, primarily focusing on late-stage projects. The company's core mission involves addressing significant unmet medical needs within the orphan drug sector, concentrating on severe and rare or niche diseases. Its current therapeutic pipeline includes two key drugs undergoing Phase IIb/III clinical trials: Aladote, which is designed to mitigate the risk of acute liver damage associated with acetaminophen/paracetamol poisoning, and Emcitate, intended for the management of MCT8 deficiency, a rare congenital disorder impacting thyroid hormone signaling. Established in 2006, Egetis Therapeutics AB (publ) is headquartered in Stockholm, Sweden, and was previously known as PledPharma AB (publ) until its name change in December 2020.
URL
https://www.egetis.com/
IPO date
Apr 07, 2011
Employees
23
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT